Prostate Cancer Trial, Recruiting (NCT06714630)

Prostate Cancer Trial, Recruiting NCT06714630 Sponsor: University of Edinburgh Condition: Prostate Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT06714630 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Prostate Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You must have received external beam radiotherapy (a type of radiation treatment) delivered using a machine called a linear accelerator
Your PSA (a prostate-related protein measured by a blood test) must have been regularly recorded after your radiotherapy treatment
You must have survived for at least 10 years after completing radiotherapy
You must have had a diagnostic CT scan (a detailed X-ray that creates cross-sectional images) taken
You must have had a CT scan taken specifically for planning your radiotherapy treatment
The detailed data from your radiotherapy treatment plan must be available
Relevant health records that can be used to identify any side effects from treatment must be available

Who may not be able to join:

You may not be eligible if you did not complete your full course of radiotherapy
You may not be eligible if there are no PSA blood test results on record for you
You may not be eligible if there are no follow-up health records available after your treatment
You may not be eligible if no scan or imaging data is available for you

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 5 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Bill Nailon, University of Edinburgh

Phone: 0044 1315371000

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06714630

Sponsor: University of Edinburgh

Phase: Not Applicable

Status: Recruiting

Condition: Prostate Cancer

Trial contact: 0044 1315371000

More information: https://clinicaltrials.gov/study/NCT06714630

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You must have received external beam radiotherapy (a type of radiation treatment) delivered using a machine called a linear accelerator
Your PSA (a prostate-related protein measured by a blood test) must have been regularly recorded after your radiotherapy treatment
You must have survived for at least 10 years after completing radiotherapy
You must have had a diagnostic CT scan (a detailed X-ray that creates cross-sectional images) taken
You must have had a CT scan taken specifically for planning your radiotherapy treatment
The detailed data from your radiotherapy treatment plan must be available
Relevant health records that can be used to identify any side effects from treatment must be available

Who may not be able to join:

You may not be eligible if you did not complete your full course of radiotherapy
You may not be eligible if there are no PSA blood test results on record for you
You may not be eligible if there are no follow-up health records available after your treatment
You may not be eligible if no scan or imaging data is available for you

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 5 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

University of Edinburgh

Registry

ClinicalTrials.gov

Start date

1 July 2024

Est. completion

30 September 2027

Where this trial is recruiting

🇬🇧 United Kingdom

Primary endpoints

PSA relapse free survival; Overall Survival; Radiotherapy Toxicity

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 5 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov